| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00467-010-1565-3 |
| P698 | PubMed publication ID | 20526631 |
| P2093 | author name string | Justin Silver | |
| Tally Naveh-Many | |||
| P2860 | cites work | Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 |
| Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway | Q28198276 | ||
| The parathyroid is a target organ for FGF23 in rats | Q28572613 | ||
| Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease | Q28583746 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. | Q33571321 | ||
| Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active | Q33736093 | ||
| Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis | Q33932297 | ||
| Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study | Q33988990 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| Initial FGF23-mediated signaling occurs in the distal convoluted tubule | Q34695191 | ||
| Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin | Q34726787 | ||
| Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. | Q35728669 | ||
| Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD | Q36667209 | ||
| Endocrine functions of bone in mineral metabolism regulation. | Q36982323 | ||
| Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia | Q37072659 | ||
| Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease | Q37440758 | ||
| Do osteocytes contribute to phosphate homeostasis? | Q37485823 | ||
| FGF23-parathyroid interaction: implications in chronic kidney disease | Q37654689 | ||
| Klotho prevents renal calcium loss. | Q41989687 | ||
| Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. | Q42493065 | ||
| Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process | Q42736434 | ||
| Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. | Q44465622 | ||
| Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression | Q44810019 | ||
| Human PTH gene regulation in vivo using transgenic mice. | Q45943472 | ||
| High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. | Q46035991 | ||
| Relationship between circulating FGF23 and total body atherosclerosis in the community | Q46519355 | ||
| Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism | Q46585085 | ||
| Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells | Q46970328 | ||
| Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane | Q47627574 | ||
| Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism | Q50073496 | ||
| Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. | Q53964449 | ||
| Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. | Q54711237 | ||
| Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism | Q81251002 | ||
| Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism | Q81853118 | ||
| Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients? | Q82875571 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 2241-2245 | |
| P577 | publication date | 2010-06-05 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | FGF23 and the parathyroid glands | |
| P478 | volume | 25 |
| Q47126125 | A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway |
| Q38348935 | Aging and uremia: Is there cellular and molecular crossover? |
| Q37984036 | Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease |
| Q34988878 | Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients |
| Q38257346 | Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones |
| Q37938913 | Bone development: overview of bone cells and signaling. |
| Q83462650 | Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta |
| Q35841012 | Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure |
| Q34281991 | Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation |
| Q49873034 | FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth |
| Q91697808 | FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model |
| Q27013868 | Familial tumoral calcinosis: a valuable vehicle for discovery |
| Q64998522 | Hepatic Osteodystrophy-Molecular Mechanisms Proposed to Favor Its Development. |
| Q38103455 | Hypophosphatemic rickets due to perturbations in renal tubular function |
| Q38104935 | Klotho and chronic kidney disease |
| Q35683762 | Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients |
| Q38737740 | Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery |
| Q37709199 | Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization. |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q37231801 | Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism |
| Q35679883 | Phosphate and Klotho |
| Q28265843 | Phosphate homeostasis and its role in bone health |
| Q42230267 | Phosphatonins: physiological role and pathological changes |
| Q37190542 | Secreted klotho and chronic kidney disease |
| Q36210285 | Update on fibroblast growth factor 23 in chronic kidney disease |
| Q34625168 | Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone. |
| Q39812781 | αKlotho and Chronic Kidney Disease |
Search more.